Financial reports
10-Q
2024 Q3
Quarterly report
7 Feb 24
10-Q
2024 Q2
Quarterly report
8 Nov 23
10-Q
2024 Q1
Quarterly report
8 Aug 23
ARS
2023 FY
Annual report to shareholders
26 Jul 23
10-K
2023 FY
Annual report
25 May 23
10-Q
2023 Q3
Quarterly report
8 Feb 23
10-Q
2023 Q2
Quarterly report
7 Nov 22
10-Q
2023 Q1
Quarterly report
9 Aug 22
10-K
2022 FY
Annual report
27 May 22
Current reports
8-K
23andMe announces CEO’s intention to pursue a potential take-private
18 Apr 24
8-K
Departure of Directors or Certain Officers
29 Mar 24
8-K
23andMe Reports Third Quarter Fiscal 2024 Financial Results
7 Feb 24
8-K
23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6
31 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K/A
Regulation FD Disclosure
1 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Nov 23
8-K
23andMe Reports Second Quarter Fiscal 2024 Financial Results
8 Nov 23
8-K
23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
6 Nov 23
8-K
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
30 Oct 23
Registration and prospectus
S-8
Registration of securities for employees
22 Mar 24
S-8
Registration of securities for employees
15 Sep 23
S-8
Registration of securities for employees
3 Mar 23
424B3
Prospectus supplement
2 Mar 23
424B3
Prospectus supplement
2 Mar 23
S-3
Shelf registration
6 Feb 23
424B3
Prospectus supplement
7 Nov 22
424B3
Prospectus supplement
4 Nov 22
POS AM
Prospectus update (post-effective amendment)
3 Nov 22
424B3
Prospectus supplement
31 Aug 22
Proxies
DEFR14A
Revised proxy
4 Aug 23
DEFR14A
Revised proxy
26 Jul 23
DEFA14A
Additional proxy soliciting materials
26 Jul 23
DEF 14A
Definitive proxy
26 Jul 23
DEFA14A
Additional proxy soliciting materials
15 Jul 22
DEF 14A
Definitive proxy
15 Jul 22
DEFA14A
Additional proxy soliciting materials
21 May 21
DEFM14A
Proxy related to merger
17 May 21
Other
EFFECT
Notice of effectiveness
3 Mar 23
CORRESP
Correspondence with SEC
27 Feb 23
UPLOAD
Letter from SEC
9 Feb 23
EFFECT
Notice of effectiveness
9 Nov 22
UPLOAD
Letter from SEC
24 Aug 22
CORRESP
Correspondence with SEC
9 Aug 22
UPLOAD
Letter from SEC
21 Jul 22
EFFECT
Notice of effectiveness
16 Jul 21
CORRESP
Correspondence with SEC
13 Jul 21
UPLOAD
Letter from SEC
13 Jul 21
Ownership
4
KATHY L HIBBS
19 Apr 24
SC 13D/A
ABeeC 2.0, LLC
17 Apr 24
4
KATHY L HIBBS
5 Apr 24
4
KATHY L HIBBS
22 Mar 24
4
KATHY L HIBBS
11 Mar 24
144
Notice of proposed sale of securities
7 Mar 24
4
KATHY L HIBBS
23 Feb 24
4
William G Richards
21 Feb 24
4
Joseph Anthony Selsavage
21 Feb 24
4
KATHY L HIBBS
21 Feb 24